Background
AML, aggressive disease
ACUTE MYELOID LEUKEMIA, AML
Acute myeloid leukemia (AML) is an aggressive disease, which requires intensive treatment strategies to achieve curation. The mainstay of intensive anti-leukemic therapy comprises an induction with anthracyclines/mitoxantrone and cytarabine, commonly applied as the so-called 7 + 3 regimen with seven days cytarabine and three days of daunorubicin. Depending on genetic risk, induction therapy can vary by formulation of chemotherapy or addition of targeted therapies. However, AML is characterized by a high relapse rate, indicating insufficient clearance of leukemia-initiating cells (Dohner et al. 